MedWatch

Devote data can give Novo more negotiation power

Detailed data from Novo Nordisk’s comparative Devote study confirms that the company’s new insulin is as safe as and markedly more effective than its rival, the top-selling Lantus from Sanofi. This information can strengthen Novo’s position in the important ongoing negotiations with US payers.

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Frontpage right now

Reuters: Kinesere vil købe J&J's diabetesforretning

Amerikanske Johnson & Johnson kan være på vej til at sælge sin forretning for diabetesudstyr for godt 24 mia. kr., efter flere kinesiske aktører ifølge Reuters har vist interesse i at overtage forretningsdelen.

Related articles